Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)

Inclusion Criteria: * Patients over 18 years old of either sex who have given their informed consent to participate in the study. * Patients with a neoplastic process, with a CVC for the administration of anti-tumoral treatment or any other treatment related to the neoplastic process. * Patients with a platelet count above 30,000/mm3. * Patients with no hemorrhagic symptomatology at the time of their inclusion Exclusion Criteria: * Patients with a history of clinically evident hemorrhagic episodes and/or with increased bleeding due to any other homeostatic alteration that contraindicates anticoagulant treatment and/or in the past two months have presented at least one of the following: active hemorrhaging or organic lesions susceptible to bleeding (e.g. active peptic ulcer, hemorrhagic cerebrovascular accident, aneurysms). * Major surgery in the past two months. * Known hypersensitivity to LMWH, heparin or substances of porcine origin. * Patients with congenital or acquired bleeding diathesis. * Damage to or surgical interventions of the central nervous system, eyes and ears within the past 6 months. * Acute bacterial endocarditis or slow endocarditis. * Patients with a history of heparin-associated thrombocytopenia. * Patients with severe renal failure (serum creatinine over 2 mg/dl) or hepatic insufficiency (with values of AST and/or ALT \> 5 times the normal value established by the reference range of the local hospital laboratory). * Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic blood pressure over 120 mmHg). * Patients with suspected inability/or inability to comply with treatment and/or complete the study. * Patients who are participating in another clinical trial or have done so in the past 30 days. * Patients with a life expectancy less than 3 months. * Women who are pregnant or breast-feeding, or with the possibility of becoming pregnant during the study. * Patients on treatment with anticoagulants or who have been on treatment during the week previous to insert the CVC (including prophylaxis with heparin for hepatic veno-occlusive disease). * Patients diagnosed with acute leukemia or awaiting a transplant from hematopoietic progenitors during the 90 days of the study.